A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine and 13-valent Pneumococcal Conjugate Vaccine in Pneumococcal Disease and 13-valent Pneumococcal Vaccine, sponsored by Pfizer. Completed at 21 sites in United States. Open to participants aged 42 Days to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-03-15.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 20th largest by enrollment, is one of 2 that started in 2009, is one of 19 in phase 3, and was the 9th registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →
13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 42 Days to 5 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 20 · Phase 4 11
First in 2004; this study’s year is marked. 2 started in 2009.
This study's enrollment of 373 is close to the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 328 across the 44 interventional studies. Of the 40 that completed or were terminated, 23 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 39th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2009, is one of 33 in phase 3, and was the 20th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal conjugate vaccine in Alaskan Native Children.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects 6 weeks to \<10 months of age with 0 prior dose of Prevnar.
Biological: 13-valent Pneumococcal Conjugate Vaccine
Subjects \<12 months of age with 1 prior dose of Prevnar.
Biological: 13-valent Pneumococcal Conjugate Vaccine
Subjects \<12 months of age with 2 prior doses of Prevnar.
Biological: 13-valent Pneumococcal Conjugate Vaccine
Subjects ≥12 months to \<2 years of age.
Biological: 13-valent Pneumococcal Conjugate Vaccine
Subjects ≥2 years to \<5 years of age
Biological: 13-valent Pneumococcal Conjugate Vaccine
4 doses of 13vPnC (0.5ml, IM) will be administered. (3 doses infant series, and 1 toddler dose)
3 doses of 13vPnC (0.5ml, IM) will be administered. (2 doses for infant series catch-up, and 1 toddler dose)
2 doses of 13vPnC (0.5ml, IM) will be administered. (1 dose infant series catch-up, and 1 toddler dose)
2 doses of 13vPnC (0.5ml, IM) will be administered. (2 catch-up dose(s) greater than 60 days apart )
1 dose of 13vPnC (0.5ml, IM) will be administered. (1 catch-up dose)
Percentage of Participants Achieving Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Level ≥0.35 Micrograms Per Milliliter (Mcg/mL) 1 Month After the Infant Series
Percentage of participants in 13vPnC Groups 1, 2 and 3 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
Time frame: 28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.
Percentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Toddler Dose
Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
Time frame: 28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Relevant Catch-Up Dose
Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
Time frame: 28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.
Percentage of Participants Achieving Serum IgG Antibody Level ≥0.35 Mcg/mL Prior to Vaccination With 13vPnC (Groups 4 and 5 Only)
Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
Time frame: 28 to 56 days before vaccination 2 for Group 4, and before the single vaccination in Group 5.
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Infant Series
Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
Time frame: 28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Toddler Dose
Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
Time frame: 28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Relevant Catch-up Dose
Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
Time frame: 28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.
Percentage of Participants Reporting Pre-Specified Local Reactions: Catch-up Dose 1
Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may have been represented in more than 1 category.
Time frame: Day 1 through Day 7 after vaccination 1 for Group 4 and after the single vaccination in Group 5.
Percentage of Participants Reporting Pre-Specified Local Reactions: Catch-up Dose 2
Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may have been represented in more than 1 category.
Time frame: Day 1 through Day 7 after vaccination 2 for Group 4
Percentage of Participants Reporting Pre-Specified Systemic Events: Catch-up Dose 1
Systemic events (any fever 38 degrees Celsius \[C\] or higher, decreased appetite, irritability, increased sleep, decreased sleep, hives \[urticaria\], and use of antipyretic medication) were reported using a diary card. Participants may have been represented in more than 1 category.
Time frame: Day 1 through Day 7 after vaccination 1 for Group 4 and after the single vaccination in Group 5.
Percentage of Participants Reporting Pre-Specified Systemic Events: Catch-up Dose 2
Systemic events (any fever 38 degrees C or higher, decreased appetite, irritability, increased sleep, decreased sleep, hives \[urticaria\], and use of antipyretic medication) were reported using a diary card. Participants may have been represented in more than 1 category.
Time frame: Day 1 through Day 7 after vaccination 2 for Group 4
Number of Cases of Invasive Pneumococcal Disease (IPD) in Participants Less Than 5 Years of Age Due to Any Serotype Contained in 13vPnC
In order to assess the impact of 13vPnC on the incidence of IPD in the Yukon Kuskokwim (YK) Delta region, the Centers for Disease Control and Prevention (CDC) Arctic Investigation Program (AIP) accessed IPD data through evaluation of ongoing statewide IPD surveillance in Alaska. The CDC's AIP followed IPD (including serotype and vaccination history) to show whether identified cases of IPD received Prevnar, 13vPnC, or both. These data were combined with statewide data and used to identify the overall trend in IPD in the YK Delta region after introduction of 13vPnC.
Time frame: Baseline to 6 months after last vaccination
Percentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Infant Series
Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
Time frame: 28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Toddler Dose
Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
Time frame: 28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Relevant Catch-up Dose
Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
Time frame: 28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal IgG Antibodies 1 Month After the Infant Series
Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.
Time frame: 28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.
GMC for Serotype-Specific Pneumococcal IgG Antibodies 1 Month After the Toddler Dose
Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.
Time frame: 28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, after vaccination 2 for Group 3.
GMC for Serotype-specific Pneumococcal IgG Antibodies 1 Month After the Relevant Catch-up Dose
Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.
Time frame: 28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.
Percentage of Participants Achieving Opsonophagocytic Assay (OPA) Titers ≥Lower Limit of Quantitation (LLOQ) Measured 1 Month After the Infant Series
Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5\*LOD for analysis.
Time frame: 28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.
Percentage of Participants Achieving OPA Titers ≥LLOQ Measured 1 Month After the Toddler Dose
Percentage of participants in 13vPnC Groups 1, 2 and 3 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5\*LOD for analysis.
Time frame: 28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.
Percentage of Participants Achieving OPA Titers ≥LLOQ Measured 1 Month After the Relevant Catch-up Dose
Percentage of participants in 13vPnC Groups 4 and 5 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5\*LOD for analysis.
Time frame: 28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.
Pneumococcal OPA Geometric Mean Titers (GMTs) 1 Month After the Infant Series
Antibody geometric mean titers as measured by OPA assay for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMTs were calculated using all participants with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.
Time frame: 28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.
Pneumococcal OPA GMTs 1 Month After the Toddler Dose
Antibody geometric mean titers as measured by OPA assay for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMTs were calculated using all subjects with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.
Time frame: 28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, after vaccination 2 for Group 3.
Pneumococcal OPA GMTs 1 Month After the Relevant Catch-up Dose
Antibody geometric mean titers as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMTs were calculated using all participants with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.
Time frame: 28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.
Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Infant Series
Time frame: 28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.
Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Toddler Dose
Time frame: 28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.
Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Relevant Catch-up Dose
Time frame: 28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.
Blood sample was optional for subjects living in the Bethel area. Active vaccination stopped when 13-valent pneumococcal conjugate vaccine (13vPnC) was commercially available in Alaska. Study ended after a 6-month follow-up for safety following the last vaccination.
| Milestone | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) | 13vPnC Group 4 (2 Catch-Up Doses) | 13vPnC Group 5 (1 Catch-Up Dose) |
|---|---|---|---|---|---|
| Started | 151 | 51 | 25 | 67 | 79 |
| Vaccinated dose 1 | 151 | 51 | 25 | 66 | 79 |
| Vaccinated dose 2 | 112 | 41 | 0 | 49 | 0 |
| Vaccinated dose 3 | 74 | 0 | 0 | 0 | 0 |
| Toddler dose | 15 | 23 | 16 | 0 | 0 |
| Completed | 141 | 48 | 23 | 63 | 79 |
| Not completed | 10 | 3 | 2 | 4 | 0 |
| Withdrew: Parent/legal guardian request | 3 | 2 | 2 | 2 | 0 |
| Withdrew: Adverse event | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator request | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Other | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
Percentage of participants in 13vPnC Groups 1, 2 and 3 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
| Percentage of Participants | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) |
|---|---|---|---|
| Common serotypes - serotype 4 | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Common serotypes - serotype 6B | 100.0 (71.5 to 100.0) | 83.3 (35.9 to 99.6) | 100.0 (15.8 to 100.0) |
| Common serotypes - serotype 9V | 100.0 (71.5 to 100.0) | 83.3 (35.9 to 99.6) | 100.0 (29.2 to 100.0) |
| Common serotypes - serotype 14 | 90.9 (58.7 to 99.8) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotype - serotype 18C | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Common serotype - serotype 19F | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Common serotype - serotype 23F | 90.9 (58.7 to 99.8) | 83.3 (35.9 to 99.6) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 1 | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 3 | 90.9 (58.7 to 99.8) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 5 | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 6A | 90.9 (58.7 to 99.8) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 7F | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 19A | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
| Percentage of Participants | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) |
|---|---|---|---|
| Common serotypes - serotype 4 | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotypes - serotype 6B | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotypes - serotype 9V | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotypes - serotype 14 | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotype - serotype 18C | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotype - serotype 19F | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotype - serotype 23F | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 1 | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 3 | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 5 | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 6A | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 7F | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 19A | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
| Percentage of Participants | 13vPnC Group 4 (2 Catch-Up Doses) | 13vPnC Group 5 (1 Catch-Up Dose) |
|---|---|---|
| Common serotypes - serotype 4 | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotypes - serotype 6B | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotypes - serotype 9V | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotypes - serotype 14 | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotype - serotype 18C | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotype - serotype 19F | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotype - serotype 23F | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Additional serotype - serotype 1 | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Additional serotype - serotype 3 | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Additional serotype - serotype 5 | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Additional serotype - serotype 6A | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Additional serotype - serotype 7F | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Additional serotype - serotype 19A | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
| Percentage of Participants | 13vPnC Group 4 (2 Catch-Up Doses) | 13vPnC Group 5 (1 Catch-Up Dose) |
|---|---|---|
| Common serotypes - serotype 4 | 50.0 (6.8 to 93.2) | 50.0 (15.7 to 84.3) |
| Common serotypes - serotype 6B | 100.0 (39.8 to 100.0) | 88.9 (51.8 to 99.7) |
| Common serotypes - serotype 9V | 100.0 (39.8 to 100.0) | 66.7 (29.9 to 92.5) |
| Common serotypes - serotype 14 | 100.0 (29.2 to 100.0) | 88.9 (51.8 to 99.7) |
| Common serotype - serotype 18C | 75.0 (19.4 to 99.4) | 33.3 (7.5 to 70.1) |
| Common serotype - serotype 19F | 100.0 (39.8 to 100.0) | 88.9 (51.8 to 99.7) |
| Common serotype - serotype 23F | 100.0 (39.8 to 100.0) | 88.9 (51.8 to 99.7) |
| Additional serotype - serotype 1 | 0.0 (0.0 to 60.2) | 12.5 (0.3 to 52.7) |
| Additional serotype - serotype 3 | 0.0 (0.0 to 60.2) | 37.5 (8.5 to 75.5) |
| Additional serotype - serotype 5 | 50.0 (6.8 to 93.2) | 100.0 (66.4 to 100.0) |
| Additional serotype - serotype 6A | 100.0 (39.8 to 100.0) | 88.9 (51.8 to 99.7) |
| Additional serotype - serotype 7F | 0.0 (0.0 to 60.2) | 33.3 (7.5 to 70.1) |
| Additional serotype - serotype 19A | 100.0 (39.8 to 100.0) | 88.9 (51.8 to 99.7) |
Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
| Percentage of Participants | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) |
|---|---|---|---|
| Common serotypes - serotype 4 | 90.9 (58.7 to 99.8) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Common serotypes - serotype 6B | 72.7 (39.0 to 94.0) | 83.3 (35.9 to 99.6) | 100.0 (15.8 to 100.0) |
| Common serotypes - serotype 9V | 81.8 (48.2 to 97.7) | 66.7 (22.3 to 95.7) | 66.7 (9.4 to 99.2) |
| Common serotypes - serotype 14 | 90.9 (58.7 to 99.8) | 83.3 (35.9 to 99.6) | 100.0 (15.8 to 100.0) |
| Common serotype - serotype 18C | 63.6 (30.8 to 89.1) | 83.3 (35.9 to 99.6) | 100.0 (29.2 to 100.0) |
| Common serotype - serotype 19F | 100.0 (71.5 to 100.0) | 66.7 (22.3 to 95.7) | 100.0 (29.2 to 100.0) |
| Common serotype - serotype 23F | 63.6 (30.8 to 89.1) | 50.0 (11.8 to 88.2) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 1 | 81.8 (48.2 to 97.7) | 83.3 (35.9 to 99.6) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 3 | 54.5 (23.4 to 83.3) | 66.7 (22.3 to 95.7) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 5 | 81.8 (48.2 to 97.7) | 83.3 (35.9 to 99.6) | 66.7 (9.4 to 99.2) |
| Additional serotype - serotype 6A | 72.7 (39.0 to 94.0) | 83.3 (35.9 to 99.6) | 66.7 (9.4 to 99.2) |
| Additional serotype - serotype 7F | 100.0 (71.5 to 100.0) | 83.3 (35.9 to 99.6) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 19A | 72.7 (39.0 to 94.0) | 50.0 (11.8 to 88.2) | 33.3 (0.8 to 90.6) |
Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
| Percentage of Participants | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) |
|---|---|---|---|
| Common serotypes - serotype 4 | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 50.0 (1.3 to 98.7) |
| Common serotypes - serotype 6B | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotypes - serotype 9V | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 50.0 (1.3 to 98.7) |
| Common serotypes - serotype 14 | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotype - serotype 18C | 100.0 (15.8 to 100.0) | 83.3 (35.9 to 99.6) | 100.0 (15.8 to 100.0) |
| Common serotype - serotype 19F | 100.0 (15.8 to 100.0) | 83.3 (35.9 to 99.6) | 100.0 (15.8 to 100.0) |
| Common serotype - serotype 23F | 100.0 (15.8 to 100.0) | 83.3 (35.9 to 99.6) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 1 | 100.0 (15.8 to 100.0) | 83.3 (35.9 to 99.6) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 3 | 50.0 (1.3 to 98.7) | 66.7 (22.3 to 95.7) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 5 | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 6A | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 7F | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 19A | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
| Percentage of Participants | 13vPnC Group 4 (2 Catch-Up Doses) | 13vPnC Group 5 (1 Catch-Up Dose) |
|---|---|---|
| Common serotypes - serotype 4 | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotypes - serotype 6B | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotypes - serotype 9V | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotypes - serotype 14 | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotype - serotype 18C | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotype - serotype 19F | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotype - serotype 23F | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Additional serotype - serotype 1 | 100.0 (39.8 to 100.0) | 66.7 (29.9 to 92.5) |
| Additional serotype - serotype 3 | 100.0 (39.8 to 100.0) | 77.8 (40.0 to 97.2) |
| Additional serotype - serotype 5 | 100.0 (39.8 to 100.0) | 88.9 (51.8 to 99.7) |
| Additional serotype - serotype 6A | 100.0 (39.8 to 100.0) | 88.9 (51.8 to 99.7) |
| Additional serotype - serotype 7F | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Additional serotype - serotype 19A | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may have been represented in more than 1 category.
| Percentage of Participants | 13vPnC Group 4 (2 Catch-Up Doses) | 13vPnC Group 5 (1 Catch-Up Dose) |
|---|---|---|
| Tenderness: Any (n=65,77) | 32.3 | 48.1 |
| Tenderness: Significant (n=63,77) | 3.2 | 9.1 |
| Swelling: Any (n=64,77) | 7.8 | 7.8 |
| Swelling: Mild (n=62,76) | 3.2 | 2.6 |
| Swelling: Moderate (n=63,77) | 3.2 | 6.5 |
| Swelling: Severe (n=63,77) | 1.6 | 2.6 |
| Redness: Any (n=65,77) | 15.4 | 13.0 |
| Redness: Mild (n=63,77) | 11.1 | 11.7 |
| Redness: Moderate (n=64,77) | 4.7 | 5.2 |
| Redness: Severe (n=63,77) | 1.6 | 2.6 |
Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may have been represented in more than 1 category.
| Percentage of Participants | 13vPnC Group 4 (2 Catch-Up Doses) |
|---|---|
| Tenderness: Any (n=49) | 36.7 |
| Tenderness: Significant (n=49) | 10.2 |
| Swelling: Any (n=48) | 10.4 |
| Swelling: Mild (n=47) | 8.5 |
| Swelling: Moderate (n=47) | 0.0 |
| Swelling: Severe (n=47) | 0.0 |
| Redness: Any (n=49) | 6.1 |
| Redness: Mild (n=48) | 4.2 |
| Redness: Moderate (n=48) | 0.0 |
| Redness: Severe (n=48) | 0.0 |
Systemic events (any fever 38 degrees Celsius \[C\] or higher, decreased appetite, irritability, increased sleep, decreased sleep, hives \[urticaria\], and use of antipyretic medication) were reported using a diary card. Participants may have been represented in more than 1 category.
| Percentage of Participants | 13vPnC Group 4 (2 Catch-Up Doses) | 13vPnC Group 5 (1 Catch-Up Dose) |
|---|---|---|
| Fever ≥38 degrees C but ≤39 degrees C (n=35,47) | 42.9 | 27.7 |
| Fever >39 degrees C but ≤40 degrees C (n=29,43) | 20.7 | 11.6 |
| Fever >40 degrees C (n=28,40) | 7.1 | 0 |
| Decreased appetite (n=66,77) | 31.8 | 24.7 |
| Irritability (n=66,77) | 53.0 | 41.6 |
| Increased sleep (n=66,77) | 33.3 | 22.1 |
| Decreased sleep (n=66,77) | 24.2 | 11.7 |
| Hives (urticaria) (n=66,77) | 3.0 | 2.6 |
| Use of medication to treat symptoms (n=65,77) | 50.8 | 33.8 |
Systemic events (any fever 38 degrees C or higher, decreased appetite, irritability, increased sleep, decreased sleep, hives \[urticaria\], and use of antipyretic medication) were reported using a diary card. Participants may have been represented in more than 1 category.
| Percentage of Participants | 13vPnC Group 4 (2 Catch-Up Doses) |
|---|---|
| Fever ≥38 degrees C but ≤39 degrees C (n=26) | 23.1 |
| Fever >39 degrees C but ≤40 degrees C (n=22) | 9.1 |
| Fever >40 degrees C (n=21) | 0.0 |
| Decreased appetite (n=49) | 22.4 |
| Irritability (n=49) | 57.1 |
| Increased sleep (n=49) | 26.5 |
| Decreased sleep (n=49) | 4.1 |
| Hives (urticaria) (n=49) | 2.0 |
| Use of medication to treat symptoms (n=49) | 42.9 |
In order to assess the impact of 13vPnC on the incidence of IPD in the Yukon Kuskokwim (YK) Delta region, the Centers for Disease Control and Prevention (CDC) Arctic Investigation Program (AIP) accessed IPD data through evaluation of ongoing statewide IPD surveillance in Alaska. The CDC's AIP followed IPD (including serotype and vaccination history) to show whether identified cases of IPD received Prevnar, 13vPnC, or both. These data were combined with statewide data and used to identify the overall trend in IPD in the YK Delta region after introduction of 13vPnC.
| Participants | 13vPnC (All Participants) |
|---|---|
| Number of Cases of Invasive Pneumococcal Disease (IPD) in Participants Less Than 5 Years of Age Due to Any Serotype Contained in 13vPnC | 0 |
Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
| Percentage of Participants | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) |
|---|---|---|---|
| Common serotypes - serotype 4 | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Common serotypes - serotype 6B | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotypes - serotype 9V | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Common serotypes - serotype 14 | 90.9 (58.7 to 99.8) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotype - serotype 18C | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Common serotype - serotype 19F | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Common serotype - serotype 23F | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 1 | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 3 | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 5 | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 6A | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 7F | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 19A | 100.0 (71.5 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (29.2 to 100.0) |
Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
| Percentage of Participants | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) |
|---|---|---|---|
| Common serotypes - serotype 4 | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotypes - serotype 6B | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotypes - serotype 9V | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotypes - serotype 14 | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotype - serotype 18C | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotype - serotype 19F | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotype - serotype 23F | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 1 | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 3 | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 5 | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 6A | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 7F | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 19A | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (15.8 to 100.0) |
Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.
| Percentage of Participants | 13vPnC Group 4 (2 Catch-Up Doses) | 13vPnC Group 5 (1 Catch-Up Dose) |
|---|---|---|
| Common serotypes - serotype 4 | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotypes - serotype 6B | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotypes - serotype 9V | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotypes - serotype 14 | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotype - serotype 18C | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotype - serotype 19F | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Common serotype - serotype 23F | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Additional serotype - serotype 1 | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Additional serotype - serotype 3 | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Additional serotype - serotype 5 | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Additional serotype - serotype 6A | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Additional serotype - serotype 7F | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
| Additional serotype - serotype 19A | 100.0 (39.8 to 100.0) | 100.0 (66.4 to 100.0) |
Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.
| mcg/mL | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) |
|---|---|---|---|
| Common serotypes - serotype 4 | 2.64 (1.55 to 4.49) | 2.11 (0.93 to 4.80) | 4.27 (0.49 to 37.05) |
| Common serotypes - serotype 6B | 2.74 (1.23 to 6.12) | 2.59 (0.55 to 12.26) | 28.60 (0.12 to 7043.76) |
| Common serotypes - serotype 9V | 1.38 (0.97 to 1.98) | 1.04 (0.46 to 2.38) | 1.60 (0.31 to 8.37) |
| Common serotypes - serotype 14 | 4.78 (1.71 to 13.33) | 4.08 (1.68 to 9.88) | 10.73 (0.06 to 1894.14) |
| Common serotype - serotype 18C | 1.83 (1.04 to 3.21) | 1.66 (0.92 to 2.98) | 2.99 (0.40 to 22.62) |
| Common serotype - serotype 19F | 3.55 (2.10 to 6.01) | 1.61 (0.65 to 4.01) | 2.37 (1.43 to 3.93) |
| Common serotype - serotype 23F | 1.54 (0.79 to 3.01) | 1.03 (0.35 to 3.04) | 3.37 (1.18 to 9.66) |
| Additional serotype - serotype 1 | 3.33 (1.68 to 6.62) | 3.02 (1.06 to 8.60) | 2.87 (0.30 to 27.24) |
| Additional serotype - serotype 3 | 0.79 (0.51 to 1.22) | 1.61 (0.62 to 4.16) | 5.07 (1.53 to 16.79) |
| Additional serotype - serotype 5 | 2.89 (1.57 to 5.31) | 1.93 (1.14 to 3.26) | 1.75 (0.25 to 12.25) |
| Additional serotype - serotype 6A | 2.19 (0.93 to 5.16) | 2.48 (0.91 to 6.78) | 5.41 (0.01 to 2495.50) |
| Additional serotype - serotype 7F | 3.34 (1.99 to 5.61) | 3.18 (1.24 to 8.12) | 6.21 (1.84 to 20.92) |
| Additional serotype - serotype 19A | 1.87 (1.11 to 3.17) | 1.35 (0.56 to 3.25) | 0.97 (0.37 to 2.53) |
Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.
| mcg/mL | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) |
|---|---|---|---|
| Common serotypes - serotype 4 | 7.16 (0.00 to 199911.7) | 2.55 (1.44 to 4.53) | 1.76 (0.00 to 4004.84) |
| Common serotypes - serotype 6B | 13.64 (0.00 to NA) | 12.01 (4.23 to 34.08) | 11.32 (0.01 to 11544.32) |
| Common serotypes - serotype 9V | 2.17 (0.01 to 373.79) | 2.20 (1.30 to 3.73) | 1.30 (0.00 to 2387.89) |
| Common serotypes - serotype 14 | 12.18 (0.06 to 2411.14) | 11.42 (5.90 to 22.12) | 8.54 (0.19 to 377.53) |
| Common serotype - serotype 18C | 2.35 (0.00 to 1681.49) | 2.22 (1.22 to 4.03) | 2.42 (0.08 to 72.55) |
| Common serotype - serotype 19F | 11.00 (0.00 to 11762036) | 2.84 (1.03 to 7.79) | 3.65 (0.00 to 130178.5) |
| Common serotype - serotype 23F | 3.79 (0.00 to 66245120) | 2.35 (0.88 to 6.27) | 3.96 (NA to NA) |
| Additional serotype - serotype 1 | 2.15 (0.00 to 9338.28) | 4.19 (1.46 to 12.02) | 16.70 (0.00 to 5685164) |
| Additional serotype - serotype 3 | 0.73 (0.00 to 276.18) | 1.32 (0.63 to 2.78) | 1.63 (1.19 to 2.23) |
| Additional serotype - serotype 5 | 4.69 (0.00 to 36146.55) | 3.56 (1.96 to 6.46) | 5.85 (0.02 to 1606.11) |
| Additional serotype - serotype 6A | 17.14 (0.00 to NA) | 7.79 (3.00 to 20.21) | 3.24 (0.01 to 1555.15) |
| Additional serotype - serotype 7F | 7.45 (0.47 to 117.40) | 5.55 (2.59 to 11.87) | 4.50 (0.05 to 440.58) |
| Additional serotype - serotype 19A | 10.53 (2.63 to 42.07) | 3.21 (1.23 to 8.39) | 8.86 (0.00 to 8014211) |
Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.
| mcg/mL | 13vPnC Group 4 (2 Catch-Up Doses) | 13vPnC Group 5 (1 Catch-Up Dose) |
|---|---|---|
| Common serotypes - serotype 4 | 4.16 (1.16 to 14.91) | 4.92 (1.94 to 12.50) |
| Common serotypes - serotype 6B | 16.49 (4.31 to 63.06) | 22.94 (10.84 to 48.52) |
| Common serotypes - serotype 9V | 3.22 (1.20 to 8.64) | 5.16 (2.34 to 11.37) |
| Common serotypes - serotype 14 | 9.02 (2.18 to 37.29) | 16.99 (6.08 to 47.48) |
| Common serotype - serotype 18C | 4.22 (2.22 to 8.05) | 5.08 (2.43 to 10.63) |
| Common serotype - serotype 19F | 3.39 (0.78 to 14.78) | 6.45 (4.23 to 9.83) |
| Common serotype - serotype 23F | 4.94 (1.82 to 13.41) | 5.41 (2.30 to 12.74) |
| Additional serotype - serotype 1 | 9.37 (2.89 to 30.34) | 1.25 (0.64 to 2.46) |
| Additional serotype - serotype 3 | 1.65 (1.13 to 2.40) | 1.91 (1.06 to 3.46) |
| Additional serotype - serotype 5 | 4.51 (2.77 to 7.34) | 2.31 (1.41 to 3.78) |
| Additional serotype - serotype 6A | 7.42 (1.77 to 31.06) | 4.46 (2.09 to 9.48) |
| Additional serotype - serotype 7F | 8.81 (3.32 to 23.39) | 3.14 (1.93 to 5.08) |
| Additional serotype - serotype 19A | 4.40 (2.96 to 6.54) | 5.61 (2.69 to 11.70) |
Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5\*LOD for analysis.
| Percentage of Participants | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) |
|---|---|---|---|
| Common serotypes - serotype 4 | 88.9 (51.8 to 99.7) | 75.0 (19.4 to 99.4) | 66.7 (9.4 to 99.2) |
| Common serotypes - serotype 6B | 100.0 (66.4 to 100.0) | 100.0 (39.8 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotypes - serotype 9V | 30.0 (6.7 to 65.2) | 0.0 (0.0 to 70.8) | 66.7 (9.4 to 99.2) |
| Common serotypes - serotype 14 | 100.0 (54.1 to 100.0) | 75.0 (19.4 to 99.4) | 100.0 (15.8 to 100.0) |
| Common serotype - serotype 18C | 100.0 (59.0 to 100.0) | 100.0 (39.8 to 100.0) | 100.0 (15.8 to 100.0) |
| Common serotype - serotype 19F | 88.9 (51.8 to 99.7) | 50.0 (6.8 to 93.2) | 0.0 (0.0 to 97.5) |
| Common serotype - serotype 23F | 88.9 (51.8 to 99.7) | 66.7 (9.4 to 99.2) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 1 | 60.0 (26.2 to 87.8) | 0.0 (0.0 to 60.2) | 33.3 (0.8 to 90.6) |
| Additional serotype - serotype 3 | 90.9 (58.7 to 99.8) | 100.0 (47.8 to 100.0) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 5 | 70.0 (34.8 to 93.3) | 60.0 (14.7 to 94.7) | 33.3 (0.8 to 90.6) |
| Additional serotype - serotype 6A | 90.0 (55.5 to 99.7) | 100.0 (47.8 to 100.0) | 100.0 (29.2 to 100.0) |
| Additional serotype - serotype 7F | 100.0 (69.2 to 100.0) | 100.0 (47.8 to 100.0) | 100.0 (15.8 to 100.0) |
| Additional serotype - serotype 19A | 80.0 (44.4 to 97.5) | 75.0 (19.4 to 99.4) | 100.0 (15.8 to 100.0) |
Percentage of participants in 13vPnC Groups 1, 2 and 3 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5\*LOD for analysis.
| Percentage of Participants | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) |
|---|---|---|---|
| Common serotypes - serotype 4 | 100.0 (15.8 to 100.0) | 50.0 (11.8 to 88.2) | 100.0 (2.5 to 100.0) |
| Common serotypes - serotype 6B | 100.0 (15.8 to 100.0) | 80.0 (28.4 to 99.5) | 100.0 (2.5 to 100.0) |
| Common serotypes - serotype 9V | 100.0 (15.8 to 100.0) | 83.3 (35.9 to 99.6) | 100.0 (2.5 to 100.0) |
| Common serotypes - serotype 14 | 100.0 (15.8 to 100.0) | 100.0 (29.2 to 100.0) | 100.0 (2.5 to 100.0) |
| Common serotype - serotype 18C | 100.0 (2.5 to 100.0) | 80.0 (28.4 to 99.5) | 100.0 (2.5 to 100.0) |
| Common serotype - serotype 19F | 100.0 (15.8 to 100.0) | 60.0 (14.7 to 94.7) | 100.0 (2.5 to 100.0) |
| Common serotype - serotype 23F | 100.0 (15.8 to 100.0) | 100.0 (47.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Additional serotype - serotype 1 | 100.0 (15.8 to 100.0) | 83.3 (35.9 to 99.6) | 100.0 (2.5 to 100.0) |
| Additional serotype - serotype 3 | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (2.5 to 100.0) |
| Additional serotype - serotype 5 | 100.0 (15.8 to 100.0) | 66.7 (22.3 to 95.7) | 100.0 (2.5 to 100.0) |
| Additional serotype - serotype 6A | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (2.5 to 100.0) |
| Additional serotype - serotype 7F | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (2.5 to 100.0) |
| Additional serotype - serotype 19A | 100.0 (15.8 to 100.0) | 100.0 (47.8 to 100.0) | 100.0 (2.5 to 100.0) |
Percentage of participants in 13vPnC Groups 4 and 5 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5\*LOD for analysis.
| Percentage of Participants | 13vPnC Group 4 (2 Catch-Up Doses) | 13vPnC Group 5 (1 Catch-Up Dose) |
|---|---|---|
| Common serotypes - serotype 4 | 100.0 (29.2 to 100.0) | 100.0 (63.1 to 100.0) |
| Common serotypes - serotype 6B | 100.0 (29.2 to 100.0) | 100.0 (54.1 to 100.0) |
| Common serotypes - serotype 9V | 100.0 (39.8 to 100.0) | 100.0 (54.1 to 100.0) |
| Common serotypes - serotype 14 | 100.0 (15.8 to 100.0) | 100.0 (54.1 to 100.0) |
| Common serotype - serotype 18C | 100.0 (29.2 to 100.0) | 100.0 (54.1 to 100.0) |
| Common serotype - serotype 19F | 100.0 (29.2 to 100.0) | 100.0 (54.1 to 100.0) |
| Common serotype - serotype 23F | 100.0 (29.2 to 100.0) | 100.0 (54.1 to 100.0) |
| Additional serotype - serotype 1 | 100.0 (39.8 to 100.0) | 87.5 (47.3 to 99.7) |
| Additional serotype - serotype 3 | 100.0 (39.8 to 100.0) | 100.0 (63.1 to 100.0) |
| Additional serotype - serotype 5 | 100.0 (39.8 to 100.0) | 75.0 (34.9 to 96.8) |
| Additional serotype - serotype 6A | 100.0 (39.8 to 100.0) | 87.5 (47.3 to 99.7) |
| Additional serotype - serotype 7F | 100.0 (39.8 to 100.0) | 100.0 (63.1 to 100.0) |
| Additional serotype - serotype 19A | 100.0 (39.8 to 100.0) | 100.0 (47.8 to 100.0) |
Antibody geometric mean titers as measured by OPA assay for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMTs were calculated using all participants with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.
| Titers | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) |
|---|---|---|---|
| Common serotypes - serotype 4 | 123 (38.4 to 390.6) | 116 (3.1 to 4294.7) | 36 (0.3 to 4185.7) |
| Common serotypes - serotype 9V | 20 (3.1 to 123.1) | 4 (NA to NA) | 120 (0.1 to 199619.2) |
| Common serotype - serotype 19F | 151 (49.6 to 457.7) | 31 (0.7 to 1348.9) | 4 (NA to NA) |
| Common serotype - serotype 23F | 299 (79.5 to 1124.8) | 81 (0.1 to 52488.1) | 566 (182.6 to 1755.9) |
| Additional serotype - serotype 1 | 41 (9.2 to 183.5) | 4 (NA to NA) | 7 (0.5 to 109.4) |
| Additional serotype - serotype 3 | 58 (28.9 to 117.7) | 82 (21.7 to 311.6) | 206 (66.1 to 639.0) |
| Additional serotype - serotype 5 | 26 (9.6 to 72.3) | 18 (2.9 to 110.8) | 9 (0.3 to 234.2) |
| Additional serotype - serotype 6A | 731 (182.2 to 2933.6) | 1069 (337.1 to 3390.4) | 984 (179.7 to 5383.5) |
| Additional serotype - serotype 7F | 1396 (790.5 to 2467.0) | 1177 (692.5 to 2001.6) | 3485 (2308.5 to 5261.5) |
| Common serotype - serotype 6B | 1280 (610.3 to 2683.5) | 1450 (370.4 to 5675.6) | 1790 (0.0 to 72147076) |
| Common serotype - serotype 14 | 332 (98.0 to 1124.2) | 71 (3.3 to 1516.0) | 449 (0.1 to 2059598) |
| Common serotype - serotype 18C | 868 (304.4 to 2475.0) | 452 (67.7 to 3023.6) | 906 (0.6 to 1340206) |
| Additional serotype - serotype 19A | 58 (17.7 to 191.3) | 158 (2.5 to 9872.6) | 380 (0.0 to NA) |
Antibody geometric mean titers as measured by OPA assay for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMTs were calculated using all subjects with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.
| Titers | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) |
|---|---|---|---|
| Common serotypes - serotype 4 | 599 (422.4 to 850.2) | 58 (2.6 to 1317.2) | 220 (NA to NA) |
| Common serotypes - serotype 9V | 428 (68.2 to 2681.9) | 460 (35.0 to 6035.8) | 2765 (NA to NA) |
| Common serotypes - serotype 14 | 775 (5.8 to 104290.7) | 551 (73.6 to 4120.2) | 779 (NA to NA) |
| Common serotype - serotype 18C | 3311 (NA to NA) | 387 (14.8 to 10145.6) | 4316 (NA to NA) |
| Additional serotype - serotype 1 | 46 (0.1 to 14754.5) | 66 (14.4 to 305.2) | 165 (NA to NA) |
| Additional serotype - serotype 3 | 159 (0.2 to 141793.2) | 138 (60.9 to 313.7) | 402 (NA to NA) |
| Additional serotype - serotype 5 | 87 (0.8 to 9175.7) | 30 (5.4 to 164.2) | 88 (NA to NA) |
| Additional serotype - serotype 7F | 4590 (258.5 to 81484.1) | 1575 (810.3 to 3061.7) | 6105 (NA to NA) |
| Additional serotype - serotype 19A | 1259 (210.3 to 7542.2) | 140 (22.7 to 860.3) | 427 (NA to NA) |
| Common serotype - serotype 6B | 1565 (0.0 to NA) | 605 (17.1 to 21473.7) | 12470 (NA to NA) |
| Common serotype - serotype 19F | 397 (0.0 to NA) | 73 (2.5 to 2087.3) | 532 (NA to NA) |
| Common serotype - serotype 23F | 227 (0.0 to NA) | 313 (30.6 to 3195.2) | 1660 (NA to NA) |
| Additional serotype - serotype 6A | 3207 (0.0 to NA) | 1688 (480.3 to 5929.3) | 6954 (NA to NA) |
Antibody geometric mean titers as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMTs were calculated using all participants with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.
| Titers | 13vPnC Group 4 (2 Catch-Up Doses) | 13vPnC Group 5 (1 Catch-Up Dose) |
|---|---|---|
| Common serotypes - serotype 4 | 594 (107.1 to 3295.5) | 1165 (261.1 to 5197.9) |
| Common serotypes - serotype 6B | 7236 (3423.7 to 15294.0) | 6795 (795.9 to 58012.5) |
| Common serotypes - serotype 9V | 2748 (457.9 to 16485.4) | 2979 (883.6 to 10040.5) |
| Common serotypes - serotype 14 | 1159 (31.2 to 42979.5) | 1547 (347.4 to 6892.2) |
| Common serotype - serotype 18C | 5910 (1824.6 to 19141.1) | 1871 (915.7 to 3824.2) |
| Common serotype - serotype 19F | 1584 (463.4 to 5417.3) | 594 (84.8 to 4164.9) |
| Common serotype - serotype 23F | 2870 (2572.2 to 3203.4) | 1240 (423.0 to 3632.5) |
| Additional serotype - serotype 1 | 402 (285.8 to 564.7) | 62 (18.0 to 211.6) |
| Additional serotype - serotype 3 | 218 (102.0 to 466.8) | 202 (136.0 to 299.3) |
| Additional serotype - serotype 5 | 128 (15.9 to 1032.0) | 63 (13.3 to 302.2) |
| Additional serotype - serotype 6A | 9067 (5187.0 to 15848.5) | 2292 (231.2 to 22724.0) |
| Additional serotype - serotype 7F | 7776 (3701.3 to 16335.8) | 6086 (2680.9 to 13818.2) |
| Additional serotype - serotype 19A | 815 (549.9 to 1206.8) | 400 (68.4 to 2344.7) |
| Participants | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) |
|---|---|---|---|
| Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Infant Series | NA | NA | NA |
| Participants | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) |
|---|---|---|---|
| Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Toddler Dose | NA | NA | NA |
| Participants | 13vPnC Group 4 (2 Catch-Up Doses) | 13vPnC Group 5 (1 Catch-Up Dose) |
|---|---|---|
| Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Relevant Catch-up Dose | NA | NA |
Collected over Randomization to 6 months after last vaccination. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 (Infant Series) | — | 21/151 (13.9%) | 11/151 (7.3%) |
| Group 2 (Infant Series) | — | 2/51 (3.9%) | 4/51 (7.8%) |
| Group 3 (Infant Series) | — | 1/25 (4%) | 1/25 (4%) |
| Group 1 (Toddler Dose) | — | 0/15 (0%) | 0/15 (0%) |
| Group 2 (Toddler Dose) | — | 0/23 (0%) | 0/23 (0%) |
| Group 3 (Toddler Dose) | — | 2/16 (12.5%) | 0/16 (0%) |
| Group 4 (2 Catch-Up Doses) | — | 3/66 (4.5%) | 1/66 (1.5%) |
| Group 5 (1 Catch-Up Dose) | — | 0/79 (0%) | 0/79 (0%) |
| Event | Group 1 (Infant Series) | Group 2 (Infant Series) | Group 3 (Infant Series) | Group 1 (Toddler Dose) | Group 2 (Toddler Dose) | Group 3 (Toddler Dose) | Group 4 (2 Catch-Up Doses) | Group 5 (1 Catch-Up Dose) |
|---|---|---|---|---|---|---|---|---|
| LaryngomalaciaCongenital, familial and genetic disorders | 0/151 | 0/51 | 0/25 | 0/15 | 0/23 | 1/16 | 0/66 | 0/79 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 1/151 | 0/51 | 0/25 | 0/15 | 0/23 | 1/16 | 0/66 | 0/79 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/151 | 0/51 | 0/25 | 0/15 | 0/23 | 1/16 | 0/66 | 0/79 |
| HerpanginaInfections and infestations | 0/151 | 0/51 | 0/25 | 0/15 | 0/23 | 1/16 | 0/66 | 0/79 |
| DehydrationMetabolism and nutrition disorders | 0/151 | 0/51 | 0/25 | 0/15 | 0/23 | 1/16 | 0/66 | 0/79 |
| Breath holdingPsychiatric disorders | 0/151 | 0/51 | 0/25 | 0/15 | 0/23 | 1/16 | 0/66 | 0/79 |
| PneumoniaInfections and infestations | 4/151 | 0/51 | 1/25 | 0/15 | 0/23 | 0/16 | 1/66 | 0/79 |
| InfluenzaInfections and infestations | 3/151 | 1/51 | 1/25 | 0/15 | 0/23 | 0/16 | 1/66 | 0/79 |
| Meningitis viralInfections and infestations | 0/151 | 0/51 | 1/25 | 0/15 | 0/23 | 0/16 | 0/66 | 0/79 |
| ApnoeaRespiratory, thoracic and mediastinal disorders | 0/151 | 0/51 | 1/25 | 0/15 | 0/23 | 0/16 | 0/66 | 0/79 |
| Event | Group 1 (Infant Series) | Group 2 (Infant Series) | Group 3 (Infant Series) | Group 1 (Toddler Dose) | Group 2 (Toddler Dose) | Group 3 (Toddler Dose) | Group 4 (2 Catch-Up Doses) | Group 5 (1 Catch-Up Dose) |
|---|---|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 9/151 | 4/51 | 1/25 | 0/15 | 0/23 | 0/16 | 0/66 | 0/79 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 0/151 | 0/51 | 0/25 | 0/15 | 0/23 | 0/16 | 1/66 | 0/79 |
| Injection site erythemaGeneral disorders | 1/151 | 0/51 | 0/25 | 0/15 | 0/23 | 0/16 | 0/66 | 0/79 |
| Injection site swellingGeneral disorders | 1/151 | 0/51 | 0/25 | 0/15 | 0/23 | 0/16 | 0/66 | 0/79 |
| ConvulsionNervous system disorders | 1/151 | 0/51 | 0/25 | 0/15 | 0/23 | 0/16 | 0/66 | 0/79 |
| CryingNervous system disorders | 1/151 | 0/51 | 0/25 | 0/15 | 0/23 | 0/16 | 0/66 | 0/79 |
| Age, Customized(Months) | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) | 13vPnC Group 4 (2 Catch-Up Doses) | 13vPnC Group 5 (1 Catch-Up Dose) | Total |
|---|---|---|---|---|---|---|
| Mean | 1.4 ± 0.6 | 4.4 ± 0.8 | 7.1 ± 1.6 | 15.2 ± 3.4 | 40.1 ± 11.1 | 12.9 ± 15.9 |
| Sex: Female, Male(Participants) | 13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose) | 13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose) | 13vPnC Group 4 (2 Catch-Up Doses) | 13vPnC Group 5 (1 Catch-Up Dose) | Total |
|---|---|---|---|---|---|---|
| Female | 73 | 23 | 11 | 36 | 47 | 190 |
| Male | 78 | 28 | 14 | 31 | 32 | 183 |
The record gives a start of Jan 2009, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine